A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary) ; PD-L1-t-haNK (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Apr 2025 Planned initiation date changed to 3 Apr 2025 to 24 Apr 2025
- 30 Mar 2025 Planned initiation date to 3 Apr 2025.
- 27 Mar 2025 Planned initiation date changed from 26 Mar 2025 to 1 Apr 2025.